NWHM was founded in August 2009 by Larry Webb, Wayne Stelmar, Joseph Davis and Tom Redwitz who still hold a combined 20% of the company. Each of them has at least 25 years of real estate experience, and some of them have worked together in John Laing Homes, which they took private in a management buyout and later sold in 2006. New Home Company operates in California, mainly in SF bay and around Sacramento. As of December 2014, they owned 22 communities and 54 communities with their join ventures.

According to management, after real estate prices collapsed in 2008, they formed the company and bought several blocks of land for attractive prices. NWHM develops and owns some properties (37% of revenues), and also builds real estate for 3rd parties (63%). However, first segment is more lucrative with 15% gross margins, compared to 4-5% fees they collect in second one.

Basically, it is a home builder located in California, building and acquiring mainly communities, either on it's own or through joint ventures. Let's look at financials. 

It is apparent that NWHM is growing it's top line quite fast, and this will accelerate in 2015 as they aim for $400 million in revenues. The company is expected to report a full year EPS of 1.35-1.45, giving it a forward P/E of around 12, and forward P/S of 0,7. For 2016, the situation looks again quite similar, where NWHM guided growth of revenue and EPS at 60% and 70% respectively. As of 31st of March, the stock had 50 million in cash, and 125 million in long-term liabilities. Company backlog grew around 5 times to $82 million in last quarter YoY, while backlog of joint ventures doubled in the same period. They seem to be executing their strategy well, and should be able to reach this year's targets easily.

US Housing market

Housing market is the cornerstone of every major economy. It's recovery has led US out of most major recessions, but this time it's really sluggish. New home sales are at levels seen during recessions in 1970s and 1980s, and house prices in certain cities still hover around 2012 lows, even though the average is steadily climbing up. Most home builders have lagged S&P500 performance in last 2 years (exception is Lennar, LEN), even though the housing market has quite improved. As a result, the whole group trades for low valuation multiples, with impressive growth rates. Situations like this offer great risk / reward ratios, and as such are very attractive investments. NWHM is the fastest growing public-listed home builder, with a great management (they made fun of each other on last conference call, too bad JP Morgan analyst didn't get the jokes), and a lot of potential. Bought the stock already with stop loss as usual. Good luck in investing!

Luxoft offers specialized software development to multinational companies in 6 main sectors: Financials, Automotive, Technology, Telecom, Travel and Energy. Around 65% of revenues come from the financials, mainly from contracts with Deutsche Bank and UBS. Most of workforce comes from Ukraine, Poland, Russia, Bulgaria (advanced projects) and Vietnam (less advanced). Customers are mostly from US, UK and Germany, with companies like Ford, Boeing, and IBM using their services. 

According to Luxoft, wage costs for qualified programmers are 75% lower in CEE (Central and Eastern Europe), than in the West. Wage inflation is around 6% in Russia and Ukraine, but they still have a huge cost advantage for many years to come. LXFT basically offers higher quality work than developers from India or Bangladesh, for a fraction of the cost in US or EU. Let's look at financials:

Luxoft has grown steadily over the past few years, gross and operating margins are recovering after a dip from 2011. Net margin was down in 2015 due to a $8 million loss on currencies (which is strange, considering their revenues are in EU and USD, while costs in currencies like Polish Zloty and Russian Ruble) and a higher tax rate. They have a special tax treatment in Russia (until 2017) and recently moved to Switzerland so tax rate shouldn't increase in the near future.

I used a three stage DCF model with these assumptions:

- profit growth of 20% for next 5 years, 10% for years 6-10, 2% thereafter
- discount rates of 6,7,8%
- 13% net profit margin

You can see that LXFT offers at least 30% potential from current prices, given assumptions above. I think it is trading so cheap because of the situation in Ukraine and Western sanctions against Russia. Another thing is that the company derives most of it's revenues from financial sector, which is currently not "popular", but much better capitalized and with a brighter future than in 2007. Be greedy when others are fearful, and be fearful when others are greedy. I am going long LXFT stock today with a stop loss like usual.

Financial pundits, news commentators, and various bloggers describe momentum investing as buying the best stocks of last 3, 6 or 12 months and holding them in hope the price advance will continue in the future. They view it as a blind strategy, where hordes of people buy a stock simply because it went up in previous period.  In their words, momentum stocks are very volatile and risky with high P/E ratios, and market participants involved in them are fools. This is a completely wrong perception. Anybody who thinks they can just buy last year's winners without any analysis and make money should visit a doctor. 

Momentum effect has been well documented by the academic community as well as fund management companies. Father of momentum investing, Richard Driehaus has long advocated this approach, along with Gerry Tsai (man who made Fidelity into a powerhouse), Martin Zweig, Philip Fisher, William O'Neil and many others. These fund managers have become legends by buying fast growing stocks in up trends for cheap prices. Do you think they just look at past year's winners and buy them every year? Probably not, nobody is that stupid.

My strategy is to use price momentum as a primary stock screener. In other words, I look at stocks making new highs for longs, and stocks going down for shorts. After that I apply various growth and value criteria (min. 10% sales growth, low debt to equity, high ROE, low P/S ratio) to narrow it down to a few stocks. These I check more thoroughly, and determine whether they have potential and are selling for a fair price.   

When a price moves up or down, there is usually a reason for it, somebody is buying or selling the stock and I have to know why. 

Wall Street and Financial Media divide stocks into various categories like growth, value, momentum, dividend and so on. They fail to see, that there is no need for division because it's all connected. As Warren Buffet said: "Growth is merely a part of value equation". When I am buying a stock, I want it to have a competitive advantage, high growth rates, be reasonably valued, and already in uptrend, if it pays a dividend that's a bonus. If it doesn't grow fast, is overvalued or in a downtrend I simply won't buy it. 

So what am I? A "value momentum growth dividend investor"! Sounds retarded, doesn't it? In fact I am just doing what every successful and intelligent investor advocates: Buy a great company for a good price and hold it as long it's making money. Price momentum is just a part (an important one in my strategy) of the whole process, and is a valuable addition to growth and value criteria in my opinion. 

I don't look at how much a stock made in the past 6 months or year. It doesn't matter at all. If you look at the winning stocks of past 100 years, they have one thing in common: all went up in price significantly and made hundreds of new highs year by year. When I look at stocks making 52-week highs today, I know there are many tomorrow's big winners there, and you just need to do the homework to identify them. Momentum definitely works as a great indicator, and does not deserve the "overvalued hype stocks" tag on it.

Do you have questions or comments about momentum investing? Post a comment below!

eHi Car Services is the largest chauffeured services car company in China, and second largest rental business in terms of fleet size. At the end of 2014, they operated more than 18000  vehicles in rental segment (70% of revenue) and 1300 vehicles in car services (30% of revenue) for a total of more than 19 000 (9800 in 2012). Fleet utilization stood at 71.8%, up from 70.5% in 2013. Number of covered cities also increased from 48 to 99. Ehi Car also operates a peer to peer sharing service similar to Zipcar.

Car rental in China is booming

Everyone knows that Chinese car industry has seen unprecedented growth in the last decade, car ownership increased significantly, although as of 2013 it was 101 cars per 1000 people, which is very low compared to USA's 800 cars per 1000 people. China has a big pollution problem, and the government already limits car ownership in certain big cities, not to mention scarce parking. Revenue in car rental market is rising much faster, from 9 billion yuan in 2008 to 34 billion yuan ($5.6 billion) in 2013  —and it is expected to reach 65 billion yuan by 2018 according to Roland Berger Strategy Consultants.

China has more than 13 000 car-rental firms, however the whole industry had a combined fleet size of only 369,000 vehicles in 2013, about 0.4% of the country’s passenger vehicles outstanding. Compare this to 1.6% in the U.S. and 2.5% in Japan. 

Competition

The industry has two major players, CAR Inc (Owned partially by Hertz Global) and eHi Car. Enterprise Holdings, largest car rental company in USA has acquired a 20% stake in EHIC, marking it's entry in China. CAR is a bigger company by any metric and also holds larger market share (7% according to Frost Sullivan), while EHIC stood at 2.1% in 2013. However, EHIC is growing revenes at a faster rate 50% vs. 30%. Both companies are investing heavily to expanding their fleets and number of cities, hence their earnings and cash flow are depressed (although CAR achieved profitability in 2014, with a 12% profit margin). Let's look at EHIC financial statements:

LDR Holding Corporation is a global medical device company focused on designing and commercializing novel and proprietary surgical technologies for the treatment of patients suffering from spine disorders. Their primary products are based on VerteBRIDGE fusion and Mobi non-fusion platforms (cervical disc), both of which are designed for applications in the cervical and lumbar spine. 

Background

In August 2013, LDRH received approval from the U.S. Food and Drug Administration, or FDA, for the Mobi-C cervical disc replacement device, the first and only cervical disc replacement device to receive FDA approval to treat both one-level and two-level cervical disc disease. LDR was founded in France by Christophe Lavigne, Patrick Richard and Herve Dinville, who still own a significant part of the company.

According to the company, their VerteBRIDGE fusion solution offers a less invasive solution to patients, and it was used more than 80 000 times globally since 2007. Their major product and growth is Mobi-C, a cervical disc replacement device, with patented mobile design, made to replicate natural anatomical movement of the spine. It is also the only FDA approved device, to show clinical superiority to two-level traditional fusion. Here are the results of tests:

• Overall trial success was 69.7% for Mobi-C and 37.4% for fusion, which represents statistical superiority (p < 0.0001).
• The rate of secondary surgeries at the operated level for Mobi-C was 3.1% versus 11.4% for fusion.
• The percentage of subjects who demonstrated adjacent segment degeneration (determined by x-ray) was:
  • 2.9% of Mobi-C patients compared to 18.1% of ACDF patients at the inferior adjacent level
  • 13.1% of Mobi-C patients compared to 33.3% of ACDF patients at the superior adjacent level
• Mean return to work time was 20.9 days shorter for Mobi-C patients compared to fusion patients.
• 78.2% of Mobi-C patients showed improvement in Neck Disability Index (NDI) based on the FDA success criteria versus 61.8% of fusion patients.

In other words, when you have problems with back or spine, doctors would put screws inside your body to fix it, which is not so comfortable and usually painful. With Mobi-C, the procedure is less invasive, and claims to offer patients better movement capabilities. The company estimates, that 30% of U.S. patients indicated for anterior surgery with symptomatic cervical disc disease may be candidates for disc replacement procedures. 

LDRH has over 400 patents globally, out of which 33 are in US, with 100 global pending, 31 in USA. The U.S. spine surgery market is expected to grow at 7.5% for the foreseeable future, with the cervical disc replacement market growing much faster.


Financials

LDRH's revenue growth has accelerated, from 16% in 2012 to 26% in 2014, and 31% in Q1 2015. More importantly, revenues from exclusive cervical products segment (Mobi-C) grew 49% (47% in Q4 2014), which shows that the product is gaining momentum among physicians in US. Approximately 20% of revenue comes from outside America. However the company still expects to spend significant amounts of money for marketing and training of doctors, and probably will not generate any profits in the future.

LDRH has 65 million in cash as of March 31st 2015, and 56 mil. in total liabilities. Inventory and receivables are growing in tandem with sales.

Competition

Market for spine treatment medical devices is competitive and crowded, with Medtronic leading the herd. However, there are hundreds of different procedures and various defects, and many companies with individual products made specifically to address these problems. LDR Holdings is one of them, it has a superior product to traditional methods of fixing certain spine disorders, with no direct competition in sight (Medtronic is developing a similar device, it's approval and launch are a question of months and years). Also, the FDA approval creates a barrier to entry, because a potential competitor has to prove that his product is not only superior to traditional methods but also to Mobi-C disc.


Summary


LDRH stock trades at a P/S multiple of 7.3, with no profits or positive cash flow. It has a product with competitive advantage, and accelerating revenue growth. I believe the health care industry will grow for years to come, with the developing countries population aging, thus increasing spending on medication. Not to mention remarkable growth in emerging economies like China and India, where the health care spending to GDP is still at very low levels. Valuation of LDR might be high, but with growth accelerating and a competitive advantage, I believe this company has a lot of potential. If my analysis is wrong, I will take a small hit and find another great stock. However, If I am right, LDRH can grow significantly for at least next few years and reward it's shareholders.

LDRH has a Zack's rating 1 (Buy), and according to insidermonkey is also held by Richard Driehaus, father of momentum investing. I am going long at open today with a stop loss. Good luck in investing!

Outside of the world of Internet marketing, Hubspot is a little known company founded in 2006 by Brian Halligan and Dharmesh Shah. It is a pioneer in field of Inbound marketing, that is SEO, content management, social media marketing, videos and others. Started out of MIT, HUBS later received venture funding from Sequoia Capital, Google Ventures, Fidelity and SalesForce.

HubSpot is a software for companies and marketing agencies, which helps devise a low-cost, modern and aimed marketing strategy. According to the company, customers no longer respond to traditional advertisements (TV, newspaper, display ads) or e-mail campaigns, instead look for opinions on products or google or social media. Their site and blogs attract 1.5 million unique visitors every month, with more than 2 million followers across Facebook, Linkedin and Twitter. Basically, they do what they say and get most customers through inbound marketing. 

Their estimated market is 3 million businesses in USA and EU, which have a web presence, while only 3% of them rely on modern marketing methods. As such, it is only at the beginning although it has already become a standard in marketing agencies (over 2200 already use it). Although the software has scale, HubSpot focuses on small and medium sized businesses (20 - 2000 employees), where it believes it has a competitive advantage and can offer the best product. According to several software review sites, they are no.1 in SEO (Search engine optimization), marketing automation and social media marketing.

Let's take a look at some numbers:

Tableau Software is a data visualization company, that aims to bring cheap analytics to millions of business owners and regular users. Based on core technologies originally developed at Stanford University, their products reduce the complexity, inflexibility any expense associated with traditional business intelligence applications. DATA makes 32% of revenues from Maintenance and Services (growing by 83%), while 68% comes from software licensing (75% growth YoY).

DATA is a first mover in Big data analytics industry, which is expected to grow by at least 25% until 2018 to $46 Billion (source ReportsnReports.com). Investment bank Cowen and Co. expects Tableau to capture 30% of business intelligence license market by 30%. According to Tableau's website, total data volume will reach 20 Exabytes by 2020, growing by 48% annually.

Companies like Microsoft and IBM have already realized the potential of this business and are developing or have already launched their own products. While they have larger resources than Tableau, no big data analytics company grows revenues and acquires customers as fast as Tableau. They are reinvesting all money into sales and R&D as can be seen on their financials:

Wall Street expects revenue growth of 70% for this stock, while management is more conservative at 45%. The tricky part about Tableau Software are it's profits. Since the company reinvests everything back in the business, it is hard to tell what it's margins will be. As such it is difficult to compare it to any other publicly available stock. Only QLIK Technologies (QLIK) comes close, trading at 5x sales (vs. 17.5 for DATA), although they grow much slower at 20% per year. Valuation is very difficult, when there are few companies to compare to and DATA generates no profits.

Why I'm going long

Tableau offers free trials on most of their products, so customers can try them out easily and decide whether to pay for more or not. Vast majority of accounts expand over time, which demonstrates that the software is popular and can spread quite quickly. Revenues are growing quickly, and Wall Street has noticed this stock some time ago, which is also reflected in it's valuation. DATA has demonstrated innovation and acquires customers at an incredible pace. Their customer conference, which is meant to build a community of enthusiasts and get feedback for their products had 180 attendees in 2008, and 5500 in 2014. At the end of last year, Tableau had 13 patents issued for their software and 25 more pending. One big risk is their issuance of stock, last year they increased number of shares outstanding by 11%, what's always a big risk in technology stocks.

I believe the company has a lot of market potential with current products, plus can develop market leading software for the future. Going long today at open with a stop loss like I always do (wouldn't recommend buying this stock without SL).

Arcotech Ltd. was established in 1981 for manufacturing internationally acceptable quality of Copper & Brass Strips and Foils. It has become one of the leading manufacturers of Copper/Brass Strips and Foils in India by creating a niche of producing micro thin foils up to 0.04 mm with close tolerance. 

The company has now expanded and increased its product range to include other Non Ferrous alloys like Phosphor Bronze, Nickel Silver, Nickel Brass, Cupro Nickel, Aluminium Bronze, Tin Bearing Copper and Silver Bearing Copper etc. These are produced in the form of semis like ingots, strips, sheets, plates, foils, copper bus bars in India. They have plans to broaden the range of products to include thingslike tubes, coin blanks, rods and wires.

Arcotech is contemplating to set up a green field project in the state of Gujarat, India to manufacture Aluminum semis. This will be an integrated facility and will prove to be a synergy to the Copper division. Aluminum demand has been growing at 10% CAGR since last 5 years and is expected to grow at 15-17% for the next five years in India.


Let's take a look at the company's financial performance:

Arcotech has grown remarkably over the past few years, although from a bottom, as copper prices declined significantly during the meltdown in 2008. And that is my major objection, I usually avoid cyclical industries like this, the company has executed well but should a recession come I believe they are toast. Arcotech is trying to diversify it's operations, but it's still relying heavily on  copper. Furthermore, margins have declined almost every year, which is a result of intense competition from bigger players like Sesa Sterlite or Hindustan Copper.

Valuation

I did a three stage DCF valuation with the following assumptions:
- 1st stage profit growth of 25% for the next 5 years
- 15% for years 6-10
- 4% terminal growth rate
- discount rates of 12%, 14%, 16%

I believe that given it's small size and rapid growth, rates of 14% and 16% are more applicable. Based on this, Arcotech offers only 16% upside in a positive scenario (with a share value of 419 Rs.). That is, if it grows by 25% and 15% respectively. Valuing cyclical companies with DCF is always tricky, as the earnings might wildly fluctuate. The stock is currently selling for a P/E of 23 and P/S of 1.2.

Summary

I didn't purchase Arcotech for a simple reason: it has no competitive advantage. It might have grown fast, but there are limits in the industry with extremely narrow margins. As Warren Buffett said: "Time is the friend of a wonderful company, and enemy of the mediocre". I will not buy such a stock, because there are so many other wonderful businesses out there.

Arvind Remedies Ltd was established in 1988 under Dr.Arvind Shah, Managing Director and CEO. The company has 30 pharmaceutical brands in 10 states. They offer various products in GP segments like Analgesics, Antioxidants, Haematinics, Antibiotic, GIT drugs, and also specialty herbal products for diabetes and herbal cream for bed sores and prevention of keloids after surgery or wounds. The stock has a market cap of 397 Rs.Cr.

The world pharma market is estimated to have grown by 2.5% in 2013 to reach the size of US $ 975 bn. While average revenue growth in  developed markets was only .36% in emerging markets of Asia Africa Australia and Latin America, the growth was about 10.7%. 
United States remains the largest pharmaceutical market globally, and also the largest generics market.

The Indian pharma industry during 2013-14 grew by mere 6.1% and reached size of approx Rs.823 bn. 
However it has been globally ranked third in terms of volume and tenth in terms of value. The market is 
expected to grow at a compounded Annual Growth Rate of 12% over the next five years. 

The key factors influence growth of healthcare sector are growth in population, increasing incidence of 
diseases, increasing affordability, rise in insurance and government schemes. 

According to their annual report, this will be the company's main focus and growth strategy:

"ARL can play vital role by going for registration of off patented products for exports and developing the outsourcing market. Key strategy will be to focus on the new and latest molecules approved by the authorities and share with top companies who can market these products, focus on additional dosages in large and small volume parenterals and injectables in powder and liquid forms."


Let's take a look at ARL financials:

Arvind's revenues and profits have skyrocketed over the past couple of years, with margins improving significantly even in the face of competition. That is a great sign, the Indian pharma market has grown steadily, but attracted a lot of competition. If Arvind Remedies can expand margins in such an environment. Long-term debt/equity is slightly above 1, which is higher than the industry average, however they have enough current assets to satisfy near term  obligations.

There are two major red flags with Arvind Remedies: inventories rising faster than sales (58% vs. 38%), and operating cash flow was negative last year, due to an increase in receivables and inventories. Rising inventories might mean, that ARL is preparing for a good season or that demand is low and the company keeps producing goods that nobody is buying. In this case, I think I will stick to the first option, as they managed this really well in the past.

Valuation

Using a 3 stage DCF model I came up with the following value:
- 16%,18%,20% discount rates
- Long term growth of 20% for the next 5 years, 10% for years 6-10
- 4% terminal growth rate

The company looks dirt cheap. Using conservative estimates (20% growth and a 20% discount rate), I arrived at a value of 756 Rs.Cr., which implies a share value of 110 Rs. That's a potential of at least 90% in that stock, and if it grows faster (last year sales and profits grew 40%), it can be a multibagger. With a P/E of 5.8 and P/S of 0.4, the stock looks like a total bargain.

Summary

The stock has been on the run after the company cancelled a planned demerger of it's new factory, which will produce generics for the US market. Arvind Remedies offers a great risk/reward scenario - if it doesn't work out, my stop loss will be hit and I will lose a small amount, however if it continues to grow like in the past, it is significantly undervalued. The stock needs to cross the 60 Rs. mark before I buy it.

I did a 3 stage DCF valuation of almost 3000 stocks using my model and these assumptions:

- For years 1-5 - Expected 5 year EPS growth rate or past 5 year sales growth, whichever is lower
- For years 6-10 - half of the mentioned rate
- discount rates of 8, 10, 12 and 14%

DCF calculations work best with companies that have stable cash flows. If a business is undergoing a rapid change, or it's earnings fluctuate every year, a DCF valuation will not be very reliable. With that said, here are some companies which are cheap, compared to their earnings or growth potential.

CLICK HERE TO DOWNLOAD THE FULL LIST OF UNDERVALUED / OVERVALUED STOCKS

Below are the most undervalued stocks, and their upside with a 14% discount rate:

Ticker                 Name                                                                Sector                             Upside                  P/E                      Market cap

Shilpi engaged in the business of the manufacturing cables for various applications used in the Telecom Sector,
Automobiles and Consumer durables sectors and the also trades in cable accessories including various types of cables and their accessories widely used in automotive, telecom infrastructure, instrumentation etc. and also deals in manufacturing various copper conductors.

The company is one of the leading manufacturers of RF cables in the country and they are actively promoting aluminum-based RF coaxial cables. Besides it is cost-efficient compared to copper cables while at the same time, the technical parameters are comparable to any other copper cable. 

Shilpi does business mainly in the following sectors:

RF CABLE MARKET
As a consequence of an explosion of mobile device usage, subscribers expect more services, data, capacity and speedier networks – whether they’re outside or inside. 

As a result, addressing the coverage, quality and capacity requirements of In Building users is mandatory. Thus IBS is going
to be critical in the coming months especially with the launch of LTE/4G services. IBS providers mainly use ½” and 7/8” RF
cable along with related accessories . Thus there will be a large requirement for these this type of cable in the coming months

AUTOMOTIVE SEGMENT
The automotive industry in India is one of the largest in the world and one of the fastest growing globally. India’s passenger car and commercial vehicle manufacturing industry is the sixth largest in the world. According to recent reports, India is set to overtake Brazil to become the sixth largest passenger vehicle producer in the world.

BUNCHED COPPER WIRE
The totalrequirements of bare copper wire/bunched copper wire is around 6 lakh M.T. per annum. Out of which,the organized sector requirement is around 3.5 Lakh M.T. and the unorganized sector accounts for around 2.5 Lakh M.T

WHITE GOODS INDUSTRY
The white goods industry plays a key role in Electrical appliances such as Washing machines, refrigerators, Microwave ovens, ironing machines and even air conditioners are considered as white goods. Shilpi believes there is a business potential of around Rs. 800~1000 crs for wire and cable industry in India in this segment.

The industry is very competitive and there is also a foreign exchange risk, as the company exports some of it's products and doesn't hedge the transactions. Let's look at financials:

The company is growing at an incredible pace, with sales rising 83% and profits 72%. Operating margins have decreased but, but net margin ticked up a bit. While profits went up almost tenfold, EPS increased only six times from 4.43 to 24.89 Rs. (58% growth YoY). This is due the increase in shares outstanding by 50% in 2012, in the recent year, this has decreased to only 7%. There haven't been any insider purchases recently.
Valuation

The most interesting about the company is it's valuation. Assuming 25% profit growth for the next 5 years, then 12.5% for years 5-10 and 2% terminal growth rate, I get the following value:

Even with a 20% discount rates and conservative growth estimates (the company grew 80% this year), Shilpi Cable Technologies looks significantly undervalued, with a potential of at least 140%. If it can grow at least 25% for the next few years, the stock could be multibagger. As you can see the stock increased sharply from 20 Rs. to 60 (market cap 310 Rs.Cr.). but I still think it's undervalued and might go higher.

I think there is no need to introduce Facebook. It is the largest social network in the world, with more than 1 billion active monthly users. Facebook, Inc. was founded in 2004 by Mark Zuckerberg, Eduardo Saverin, Andrew McCollum, Dustin Moskovitz and Chris Hughes and is headquartered in Menlo Park, California. On Facebook, users can post statuses, add friends, send messages, join groups, like posts or pages, play games and all other social stuff.

FB started with a bad IPO, after which the stock dropped almost 50%. However Facebook shares recovered and have been reaching all-time highs ever since.

Revenues have grown almost 10-fold in the past 5 years, while profits increased by 700%. Net income margin has gone down, but on the positive side, free cash flow shot up. For 2015, analyst are estimating EPS growth of 30% to 1.56 USD per share. For the next 5 years, Wall Street expects growth of 37%.

EPS estimates

Valuation

If I take the growth that analysts are expecting for the next 5 years, then take half of that for years 5-10 (18.5%) and assume a 2% discount rate, the Facebook's stock value is as follows:

Even after optimistic assumptions, FB stock doesn't offer that much upside. Of course a DCF valuation is only a rough guide, if Facebook can grow faster than everybody expects it's value is much higher. Compared to similar companies, only Twitter grew faster, Facebook is selling for P/S ratio of almost 20 and a 2015 forward P/E of 37.3.

So to summarize, Facebook looks reasonably valued at current levels and doesn't offer so much upside. Furthermore, the stock is sold heavily by insiders (almost 1 million shares in July alone) and the last buy was in August of 2012. It's a good company but I do not like the stock at these levels, so I decided not to buy it.

Michael Kors is  global luxury lifestyle brand led by a renowned and award-winning designer Michael Kors. The company has successfully expanded beyond apparel into accessories (including handbags, small leather goods, eyewear, jewelry and watches) and footwear, with a presence in 74 countries.

The company's sales and profits shot up like a rocket along with rising margins. In the recent year, they posted 51% growth in sales and a 66% rise in profits. The stock currently holds a Zacks Rank 2, and is known for positive earnings surprises. EPS estimates have increased from 3.82 90 days ago to 3.92 now. Analysts are predicting 24% EPS growth for the next 5 years.

Valuation

Using the 24% growth rate for valuation, with 12% for years 5-10, I arrived at the following value:

KORS appears to be reasonably valued at current levels. If it can achieve higher growth rates, it's definitely worth more, but I think it can't expand margins that much, so most of it will have to come from rising sales. Investors like Stephen Mandel and Joel Greenblatt still hold the stock. However, I am selling it today because KORS has broken several technical levels on the way down, and I never hold declining momentum stocks. If it resumes it's uptrend, I might be a buyer again, but right now I'm out.

I have created a three-stage DCF model to value more than 500 Indian stocks. The valuation was done with the following assumptions:

- Growth for the next 5 years - Half of the past 5-year profit or sales growth (whichever is lower)
- Growth for the years 5-10 - Half of the above mentioned rate
- Terminal growth rate of 2%
- Discount rates of 10%, 12%, 14% (for smaller companies it's best to use 14%, for larger ones use 10-12%)
- profit for the last 12 months

FULL LIST OF 540 UNDERVALUED / OVERVALUED INDIAN STOCKS

Valuing so many stocks is a challenge, given that each one has unique fundamentals and expected growth. I just did a calculation of what are the companies worth, if they can maintain only half of their past growth in the future. DCF models work only with companies which have stable cash flow and are usually in a mature phase. Companies with negative earnings were omitted. Some values might be unreliable, if there is a big difference in expected growth rates in the past and analyst projections for the future.

Here are some notable examples (using discount rates of 10%, 12%, 14%), a negative value means a stock is overvalued, positive is undervalued:
Name                                                                        Market cap (Rs.Cr.)      10%                    12%                         14%